|
- Terray Therapeutics: Everything small molecule drug discovery should be
Terray exists to change the way experimentation and computation work together We believe high-quality data at scale is the key to unlocking generative AI for small molecules
- Terray’s AI Platform Finds Drugs in Unseen Chemical Space, Achieves BMS . . .
“The core platform at Terray is to rapidly iterate around novel areas of chemical space to solve what couldn’t be solved before,” emphasized Berlin in an interview with GEN
- Terray Therapeutics aims for the clinic by 2026
When Terray Therapeutics launched in 2022, brothers Jacob and Eli Berlin told C EN that the firm was mapping the interactions between small molecules and drug targets
- Terray Therapeutics Achieves AI-Enabled Drug Discovery . . . - BioSpace
Terray is a chemistry-first, AI-native biotechnology company founded at the convergence point of machine intelligence, human intellect, and medicine The company continues to grow its own dataset, refine its own hardware, and train its own AI to turn impossible drug discovery challenges into inevitable small-molecule solutions
- How A. I. Is Revolutionizing Drug Development - The New York Times
Terray is developing new drugs for inflammatory diseases including lupus, psoriasis and rheumatoid arthritis The company, Dr Berlin said, expects to have drugs in clinical trials by early 2026
- Terray assembles $120M series B to push AI-powered small molecules into . . .
Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small molecule drug development New investor Bedford Ridge Capital and existing investor NVentures—NVIDIA’s VC arm—led the funding round, which was double the size of Terray’s series A, according to an Oct 17 release
- Platform - Terray Therapeutics
We experiment beyond limits to design smarter Our experimental platform is built for generative AI-driven drug discovery, integrating chemical experimentation and computation on an unprecedented scale We explore molecules and targets more broadly and deeply with a sophisticated combination of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and
- Everything small molecule drug discovery should be - Terray Therapeutics
Terray exists to change the way experimentation and computation work together We believe high-quality data at scale is the key to unlocking generative AI for small molecules
|
|
|